← FDA DRUG APPROVALS
FDA ANDA · ANDA217387
LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024%
Sponsor: GLAND
APPLICATION
ANDA217387
TYPE
ANDA
ORIGINAL APPROVAL
2025-04-29
LATEST ACTION
2025-04-29
ROUTE
OPHTHALMIC
DOSAGE FORM
SOLUTION/DROPS
MARKETING STATUS
Prescription
Products
LATANOPROSTENE BUNODPrescription
LATANOPROSTENE BUNOD 0.024% · SOLUTION/DROPS · OPHTHALMIC
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.